A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate pharmacokinetics (what body does to medication),
safety, tolerability, and efficacy (effectiveness) of darunavir with low-dose ritonavir
(DRV/rtv) administered once daily, in combination with an investigator-selected background
regimen consisting of other antiretrovirals (ARVs) ie, 2 nucleoside/nucleotide reverse
transcriptase inhibitors (NRTIs), in treatment-naive (never treated before) HIV-1 infected
adolescents aged from 12 to <18 years and weighing at least 40 kg.